PeerVoice Heart & Lung Audio

By PeerVoice

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

  1. 1.
    Raising the Bar in Heart Failure Management: 2021 Congress Updates on SGLT2 Inhibitors
    12:48
  2. 2.
    ASCVD: Reducing the Struggle of Keeping LDL-C at Recommended Levels
    25:24
  3. 3.
    Expanding Treatment Options in MET Exon 14-Skipping NSCLC: Clinical Insights From 2021 Virtual Congresses
    8:52
  4. 4.
    Raising the Bar in Heart Failure Management: 2021 Congress Updates on SGLT2 Inhibitors
    10:45
  5. 5.
    Evaluating the Evidence for Managing CKD: Highlights From World Congress of Nephrology 2021
    8:44
  6. 6.
    Checking In on Checkpoint Inhibitors: Current and Emerging Strategies for High PD-L1–Expressing Tumours in Advanced NSCLC
    29:24
  7. 7.
    "Improving Outcomes in Early-Stage EGFR-Mutant NSCLC: What Pathologists Can Do"
    13:19
  8. 8.
    Reassessing What’s Possible in Early-Stage EGFR-mutant NSCLC: Insights from the Latest Data
    40:45
  1. 9.
    Best Practices in Early-Stage EGFR-Mutant NSCLC: What Surgeons Need to Know
    29:16
  2. 10.
    Evolving Treatment Paradigm in Early-Stage EGFR-Mutant NSCLC: A Primer for Medical Oncologists
    16:21
  3. 11.
    Best Practices in Early-Stage EGFR-Mutant NSCLC: A Primer for Radiation Oncologists
    18:48
  4. 12.
    Improving Outcomes in Localised EGFR-Mutant NSCLC: Perspectives for Pulmonologists
    26:24
  5. 13.
    "Setting New Goals for Slowing Progression in Chronic Kidney Disease: What Is Possible With GLP-1 RAs?"
    39:04
  6. 14.
    Understanding Hypercapnia in Adult Respiratory Distress Syndrome: The Quest for Optimal Patient Outcomes
    12:56
  7. 15.
    GnRH Antagonist vs LHRH Agonist: To Desensitize or To Inhibit, That Is the Question!
    19:14
  8. 16.
    Stroke Prevention, Type 2 Diabetes, and GLP-1 Receptor Agonists: What Neurologists Need to Know
    44:48
  9. 17.
    Modern Management of Chronic Kidney Disease: A Look to the Future
    10:33
  10. 18.
    Cardiovascular Risk and Prostate Cancer: Clinical Perspectives on ADT
    22:25
  11. 19.
    Simplifying Fluid Therapy: Critical Care for the Critically Ill
    17:11
  12. 20.
    SGLT2 Inhibition for HF: Evidence From Virtual Scientific Sessions 2020
    37:43
  13. 21.
    A Look at Emerging SMA Outcomes: Highlights of WMS 2020
    9:12
  14. 22.
    Modern Management of Chronic Kidney Disease: A Look to the Future
    15:04
  15. 23.
    Practice Challenges in Advanced EGFR-Mutant NSCLC: Clarifying First-Line Strategies
    25:12
  16. 24.
    Transforming Management of Early-Stage EGFR-Mutant NSCLC: Insights From the Latest Data
    18:49
  17. 25.
    Defining Control in Moderate-to-Severe Asthma: Where Are We Now and What Can We Do?
    18:40
  18. 26.
    Best Practices for MET Mutation Testing in NSCLC: The Role of the Oncologist and the Pathologist
    16:37
  19. 27.
    New Targets in Heart Failure: Congress Updates on SGLT2 Inhibitors
    12:32
  20. 28.
    Halting the Cascade of Chronic Kidney Disease: Can We Catch Patients Before They Fall?
    36:03
  21. 29.
    A Look at Emerging SMA Outcomes: Highlights of CureSMA 2020
    9:56
  22. 30.
    A Look at Emerging SMA Outcomes: Highlights of EAN 2020
    9:52
  23. 31.
    Deciphering the Role of MET Alterations in Advanced NSCLC: Unmet Needs
    15:42
  24. 32.
    New Targets, New Hope in SMA: A 2020 Congress Coverage
    8:18
  25. 33.
    Extending Your Interdisciplinary Understanding of IL-6R Inhibitors in Rheumatoid Arthritis
    1:15:18
  26. 34.
    New Targets, New Hope in SMA: A 2020 Congress Coverage
    27:48
  27. 35.
    Managing Complicated Cases in Type 2 Diabetes
    14:24
  28. 36.
    Individualising Stroke Prevention in Older Adults With Atrial Fibrillation (How I Treat)
    14:27
  29. 37.
    Acute Polyneuropathy With Abdominal Pain: Could It be Acute Hepatic Porphyria?
    15:02
  30. 38.
    Imagining a World Without Hepatitis C Virus: A Call to Action
    10:03
  31. 39.
    Heart Matters in T2DM: The Experts Weigh In
    25:39
  32. 40.
    Individualising HIV Care to Optimise Outcomes: Clinical Points of View and Practical Considerations for Switching ART
    23:23
  33. 41.
    "Managing Stroke Risk Due to Atrial Fibrillation in Older Patients: Expert Perspectives"
    21:30
  34. 42.
    Managing Lipid-Related Cardiovascular Risk: What We Know Now
    19:23
  35. 43.
    Setting a Path for Success in Type 2 Diabetes: What We Know Now
    1:11:20
  36. 44.
    Warming Up to Novel Approaches for Primary Cold Agglutinin Disease: Strategies for Correct Diagnosis and Optimal Treatment
    16:08
  37. 45.
    Evaluating the Latest Data in Ulcerative Colitis
    17:29
  38. 46.
    PARP Inhibitors for Ovarian Cancer: Making the Right Choices at the Right Times
    9:52
  39. 47.
    Getting at the Heart of Comprehensive Disease Control in Type 2 Diabetes: What’s New?
    1:17:18
  40. 48.
    Paving the Way to Better Outcomes in EGFR-Mutant NSCLC: Time to Take a Step Further?
    1:07:42
  41. 49.
    Expert Advice on Uncontrolled Asthma: Should I Consider a Biologic for This Patient?
    25:01
  42. 50.
    Meeting the Clinical Challenge: Individualising Anticoagulation for Patients With AF and ACS
    23:25

Listen to PeerVoice Heart & Lung Audio now.

Listen to PeerVoice Heart & Lung Audio in full in the Spotify app